Genitourinary Syndrome of Menopause (GSM): What It Is and What Helps

Genitourinary syndrome of menopause (GSM) describes a group of genital, sexual, and urinary symptoms caused by declining estrogen and other sex hormones during and after the menopause transition — including vaginal dryness, burning or irritation, pain during sex, urinary urgency, and recurrent UTIs. It's common, it's often under-discussed, and unlike some menopause symptoms, it frequently doesn't improve on its own. Effective treatments exist, spanning nonprescription and prescription options.

GSM Symptoms at a Glance

What does "genitourinary" actually mean here?

This term is doing real work, and it's worth understanding why. "Genito" refers to vulvar, vaginal, and sexual tissues and symptoms. "Urinary" refers to urethral and bladder-related symptoms. GSM is broader than "vaginal dryness" — it's the same underlying hormonal change affecting a connected set of tissues that don't get discussed together nearly often enough, even though they're physiologically linked.

Why the name changed

You may have heard this called vaginal atrophy, vulvovaginal atrophy, or atrophic vaginitis — these terms are still used in some clinical contexts and aren't necessarily wrong. In 2014, The Menopause Society (then NAMS) and the International Society for the Study of Women's Sexual Health introduced "genitourinary syndrome of menopause" specifically because the older terms undersold the full picture — particularly the urinary symptoms, which are just as real and just as connected to the same hormonal cause, but easy to miss if you're only thinking about vaginal tissue.

What actually causes GSM

Declining estrogen — along with other sex hormones — leads to real, measurable changes in vulvar, vaginal, and urinary tract tissue: reduced blood flow, thinning of the vaginal lining, decreased elasticity, reduced natural lubrication, and shifts in vaginal pH that also affect the vaginal microbiome. These tissue-level changes are why GSM isn't simply "dryness" — it reflects a genuine shift in the tissue itself, not just a lack of moisture on the surface.

When GSM can begin

GSM is associated with declining estrogen, so while it becomes more common around and after menopause, it isn't limited to postmenopausal women. Symptoms can begin during perimenopause, as hormone levels start fluctuating and trending downward. It's also relevant in surgical menopause, medically induced menopause, and for women on anti-estrogen cancer treatment (like aromatase inhibitors), where the hormonal shift can be more abrupt and pronounced than in natural, gradual perimenopause.

GSM vs. vaginal dryness

Vaginal dryness can be one symptom of GSM — but it isn't the whole syndrome, and not every case of vaginal dryness is necessarily GSM. Other factors, including certain medications, allergens, hygiene products, and other health conditions, can also cause vaginal dryness. If dryness is persistent, evaluation helps confirm the actual cause rather than assuming.

Does GSM go away on its own?

Generally, no — and this is one of the more important things to understand about GSM, especially compared to symptoms like hot flashes, which for many women improve or resolve over time without treatment. GSM often persists or even progresses without treatment, because it reflects an ongoing tissue-level change tied to sustained lower estrogen, not a temporary adjustment period. This isn't meant to alarm you — it's meant to correct a common and understandable assumption that GSM, like hot flashes, will simply pass with time. For a lot of women, it won't, which is exactly why understanding your treatment options matters.

Could this be something else? GSM vs. other conditions

GSM vs. yeast infection. Burning, itching, and irritation can overlap between the two. Repeatedly self-diagnosing "recurring yeast infections" without evaluation can mean missing GSM (or another condition) as the actual, ongoing cause. Persistent or recurring symptoms deserve a real look rather than repeat over-the-counter treatment.

GSM vs. UTI. This is a genuinely important distinction. GSM can cause urinary burning, urgency, and frequency that closely resembles a UTI — but GSM and true UTIs can also coexist, and one doesn't rule out the other. Burning with urination doesn't automatically mean GSM, and it doesn't automatically mean infection either. Urine testing or clinical evaluation is often the only reliable way to tell the difference, especially with recurring symptoms.

Other conditions worth knowing about: bacterial vaginosis, sexually transmitted infections, vulvar dermatitis, lichen sclerosus, vulvodynia, pelvic floor dysfunction, certain medication side effects, and conditions like Sjögren syndrome can all produce genital or urinary symptoms that resemble GSM. This isn't meant to be an exhaustive differential diagnosis — it's meant to make one point clearly: dryness, burning, itching, urinary symptoms, and painful sex shouldn't be automatically assumed to be GSM without some form of evaluation, especially if symptoms are new, severe, or not improving with basic care.

Recurrent UTIs after menopause

This deserves its own real attention. An estimated 10–15% of women over 60 experience recurrent UTIs (generally defined as two or more UTIs in six months, or three or more in a year) — a meaningfully increased rate compared to earlier in life. This connects directly to GSM: declining estrogen changes vaginal pH and the vaginal microbiome, reducing protective lactobacilli and making the vaginal and urinary environment more hospitable to the bacteria that cause UTIs. Vaginal estrogen has real, growing evidence — including randomized trial data — supporting its use in reducing recurrent UTI frequency in postmenopausal women, through its effect on restoring vaginal pH and flora. This doesn't mean it prevents every UTI, but it's a genuinely well-supported, often underused option worth discussing with a provider if recurrent UTIs are part of your experience.

How GSM is diagnosed

Clinicians typically evaluate GSM through your reported symptoms, medical and medication history, menopause status, and a pelvic or vulvar examination that can reveal characteristic tissue changes. Urinary symptoms may warrant urine testing, particularly to distinguish GSM-related symptoms from an actual infection or to identify a true UTI happening alongside GSM.

Do you need a hormone test for GSM?

No — GSM is generally evaluated based on symptoms and clinical/physical findings, not a serum estrogen level. A blood hormone test isn't typically part of a GSM evaluation, though your provider may order other tests (like a urine culture) if infection or another condition needs to be ruled out.

Everyday life, not just sex

GSM symptoms can affect daily comfort, exercise, how clothing feels, sitting for long periods, sleep, and overall quality of life — not only sexual activity. It's worth naming that clearly, because a lot of GSM content reduces the whole topic to painful sex, which undersells how much this can affect ordinary daily comfort. And painful sex itself deserves to be taken seriously on its own terms — it shouldn't simply be accepted as an inevitable part of getting older, even though treatment doesn't resolve every possible cause of sexual pain (pelvic floor dysfunction, for instance, may need its own targeted care alongside GSM treatment).

When to see a healthcare professional

Reach out for persistent vaginal or vulvar symptoms, painful sex, bleeding after sex, recurrent urinary symptoms or UTIs, new discharge or odor, visible vulvar changes, unexplained pelvic pain, or symptoms that aren't improving with over-the-counter measures. You don't need to wait until symptoms feel severe or embarrassing — this is one of the more treatable parts of hormone change, and there's no reason to manage it alone longer than necessary.

What actually helps: GSM treatment options

Vaginal moisturizers

Used regularly (not just around sexual activity), vaginal moisturizers are absorbed into vaginal tissue and designed to provide longer-lasting relief from dryness than a lubricant. They're a reasonable first-line, nonprescription option, though they don't reverse the underlying tissue changes GSM causes — they manage a symptom rather than treating the cause.

Lubricants

Used specifically during sexual activity to reduce friction and discomfort. Lubricants are not the same as moisturizers — they serve a different purpose (immediate friction reduction, not ongoing tissue hydration) and don't address dryness outside of sexual activity. Water-based and silicone-based options each have different handling considerations (silicone-based lasts longer but isn't compatible with all silicone products; water-based is generally compatible with more materials but may need to be reapplied more often).

Low-dose vaginal estrogen

This is one of the most effective, well-established GSM treatments, and it's genuinely different from systemic hormone therapy — a distinction worth understanding clearly rather than assuming they're interchangeable. Low-dose vaginal estrogen (available as a cream, tablet/insert, or ring) acts primarily on local vaginal, vulvar, and urinary tissue, with generally low systemic absorption — though "generally low" is a more accurate description than "zero," since some systemic absorption does occur, particularly in the first weeks of use before tissue is restored. It can meaningfully improve vaginal dryness, tissue elasticity, painful sex, and — as discussed above — recurrent UTI frequency. Most current guidance does not require adding a progestogen alongside low-dose vaginal estrogen for endometrial protection, since systemic absorption at approved doses is not considered a significant endometrial stimulation concern — a genuinely different rule than for systemic estrogen therapy, and a common point of confusion worth clarifying directly. Current guidance also supports continuing treatment as long as it's helping, since symptoms commonly return when treatment stops — there's no standard arbitrary stopping point.

Vaginal DHEA (prasterone)

FDA-approved specifically for moderate-to-severe painful sex related to GSM. Here's the nuance worth getting right: prasterone is often casually described as "non-hormonal," but that's not quite accurate. It's a synthetic form of DHEA that vaginal tissue itself converts locally into estrogen and androgens after administration — so it works through sex hormone pathways, even though it isn't estrogen itself and isn't administered as one. It's a genuinely different mechanism from vaginal estrogen, but it's not accurately described as hormone-free either.

Ospemifene

An oral medication and a selective estrogen receptor modulator (SERM) — meaning it acts on estrogen receptors in some tissues while behaving differently in others, rather than being estrogen itself. FDA-approved for painful sex related to menopause-associated vaginal changes. Because of its estrogen-receptor activity, it carries some similar precautions to estrogen-containing products, despite not being estrogen.

Systemic hormone therapy

Systemic hormone therapy can improve GSM symptoms as part of its broader effects, but it is not required for GSM specifically — women whose primary or only symptoms are genitourinary often do well with local treatment alone, without needing to take on the broader systemic exposure of hormone therapy used mainly for symptoms like hot flashes. (Full comparison: [Hormone Therapy vs. Non-Hormonal Support →].)

Pelvic floor physical therapy

Particularly useful when pelvic floor dysfunction, guarding, or pain with penetration coexist with GSM — which happens more often than most women realize, since chronic discomfort can lead to protective muscle tension that becomes its own contributing problem. Pelvic floor therapy doesn't reverse estrogen-related tissue changes, but it can meaningfully address the muscular and pain-pattern component that sometimes develops alongside GSM.

Vaginal dilators

Can be a useful, gradual tool for women experiencing pain with penetration, often used alongside other GSM treatment or pelvic floor therapy rather than as a standalone approach. There's nothing unusual or last-resort about using them — they're simply one practical tool among several.

Regular sexual activity or vaginal stimulation

Some evidence suggests regular sexual activity or vaginal stimulation may support vaginal tissue health, though this shouldn't be read as a requirement — no woman needs to have sex to maintain vaginal health, and this is a supporting factor among several, not a treatment on its own.

Laser and energy-based devices — a genuinely important caution

This deserves direct, plain language given how aggressively these devices are marketed. In July 2018, the FDA issued a formal safety communication stating that energy-based "vaginal rejuvenation" devices marketed for menopause-related symptoms, incontinence, or sexual function have not been cleared or approved for those specific uses, and that safety and effectiveness have not been established — a warning that remains current. The Menopause Society has taken a more measured position, acknowledging these devices might eventually prove useful for some women but calling for more rigorous, sham-controlled clinical trials before they can be broadly recommended. ACOG has backed the FDA's concerns. This is a real gap between marketing claims and regulatory/evidence status — worth knowing plainly before considering this option, and worth discussing directly with a provider rather than a device marketer.

GSM Treatment Options Compared

Vaginal estrogen vs. systemic hormone therapy — the core distinction

Low-dose vaginal estrogen targets local vaginal, vulvar, and urinary tissue directly, with relatively low (though not zero) systemic exposure. Systemic hormone therapy raises circulating hormone levels throughout the body and is used for broader menopause indications like hot flashes and night sweats, in addition to any GSM benefit it provides along the way. The risk conversations for the two are not necessarily identical — this is a meaningful distinction, not just a difference in delivery method, and it's worth understanding clearly before assuming vaginal estrogen carries the same considerations as systemic therapy.

Breast cancer and GSM: real nuance, not a blanket answer

This deserves care, because both "women with breast cancer can't use anything" and "vaginal estrogen is completely safe after breast cancer" oversimplify a genuinely more complex picture.

ACOG's position, most recently reaffirmed, states that current evidence does not show increased cancer recurrence risk with vaginal estrogen use in women with a current or past breast cancer history, and supports individualized decision-making in coordination with oncology. Nonhormonal approaches (moisturizers, lubricants) are typically considered first for women with a cancer history, given the additional considerations involved.

Here's the nuance that's easy to miss: treatment history matters, and tamoxifen and aromatase inhibitors are genuinely different situations. Evidence for vaginal estrogen alongside tamoxifen is more reassuring — current data doesn't show increased recurrence risk. Aromatase inhibitors are a more complex picture: because AIs work by aggressively suppressing the body's estrogen production, even the relatively low systemic absorption from vaginal estrogen can, in some women, produce measurable — sometimes sustained — increases in serum estradiol, according to recent pharmacokinetic research. This doesn't mean vaginal estrogen is off the table for women on aromatase inhibitors, but it does mean this specific combination deserves closer, individualized, oncology-coordinated monitoring and decision-making rather than an assumption of equivalent safety to the tamoxifen situation. Nonhormonal options (moisturizers, lubricants, pelvic floor therapy, and in some cases ospemifene, which has its own separate considerations to discuss with an oncology team) are often tried first in this specific population.

The honest summary: this is genuinely individual, genuinely worth an oncology-coordinated conversation, and genuinely not something to self-manage or assume either way based on general information alone — including this article.

Surgical and medically induced menopause

GSM can be especially relevant after bilateral oophorectomy, since the abrupt hormone loss from surgical menopause can bring on GSM symptoms faster and sometimes more intensely than the gradual natural transition. (Full context: [Surgical Menopause: What Changes Overnight →].) The same applies to medically induced menopause from chemotherapy, radiation, ovarian suppression, or aromatase inhibitors specifically — treatment considerations can differ based on the underlying condition and treatment plan, which is exactly why the breast-cancer nuance above matters so much for this population specifically.

Frequently asked questions

What is genitourinary syndrome of menopause? A group of genital, sexual, and urinary symptoms — including vaginal dryness, burning, painful sex, urinary urgency, and recurrent UTIs — caused by declining estrogen and other sex hormones during and after the menopause transition.

What are the symptoms of GSM? Vulvar and vaginal symptoms (dryness, burning, itching, irritation), sexual symptoms (pain during sex, reduced comfort), and urinary symptoms (urgency, frequency, burning, recurrent UTIs).

Can GSM start during perimenopause? Yes — GSM is tied to declining estrogen, which begins during perimenopause, not only after the final menstrual period.

Does GSM go away? Generally not on its own — unlike hot flashes, GSM often persists or progresses without treatment, since it reflects ongoing tissue changes rather than a temporary adjustment.

Is vaginal dryness the same as GSM? Vaginal dryness can be one symptom of GSM, but GSM is broader, and not every case of vaginal dryness is necessarily GSM — other causes exist.

Can menopause cause urinary burning? Yes, as part of GSM — but burning with urination can also indicate an actual UTI, and the two can coexist, so evaluation is often needed to tell the difference.

Why do UTIs become more common after menopause? Declining estrogen changes vaginal pH and the vaginal microbiome, reducing protective bacteria and making the vaginal and urinary environment more susceptible to UTI-causing bacteria.

Can GSM feel like a UTI? Yes — GSM-related urinary symptoms can closely resemble a UTI, which is why testing or clinical evaluation matters for recurring symptoms.

What is the difference between vaginal moisturizer and lubricant? Moisturizers are used regularly for ongoing dryness relief; lubricants are used during sexual activity specifically to reduce friction. They serve different purposes and aren't interchangeable.

Is vaginal estrogen the same as HRT? No — low-dose vaginal estrogen targets local tissue with relatively low systemic absorption, while systemic hormone therapy raises circulating hormone levels throughout the body for broader menopause symptoms.

Does vaginal estrogen enter the bloodstream? Some systemic absorption does occur, particularly early in treatment, though it's generally low — "low" is more accurate than "none."

Do you need progesterone with vaginal estrogen? Generally, no — current guidance doesn't require it for most women at approved low doses, unlike the requirement for systemic estrogen therapy in women with a uterus.

Can vaginal estrogen be used long term? Yes — current guidance supports continuing treatment as long as it's helping, since symptoms often return when treatment stops.

Can vaginal estrogen help prevent recurrent UTIs? Yes, with real supporting evidence, including randomized trial data — through its effect on restoring vaginal pH and healthy vaginal flora.

Can breast cancer survivors use vaginal estrogen? Often yes, through individualized, oncology-coordinated decision-making — though the specific cancer treatment matters: evidence is more reassuring with tamoxifen than with aromatase inhibitors, which require closer monitoring given more complex pharmacokinetic evidence.

What is vaginal DHEA? A vaginal insert (prasterone) that vaginal tissue converts locally into estrogen and androgens — FDA-approved for painful sex related to GSM. Not accurately described as simply "non-hormonal."

Is prasterone a hormone? It's converted into hormones (estrogen and androgens) locally within vaginal tissue after administration — so while it isn't administered as estrogen itself, it isn't accurately called non-hormonal either.

What is ospemifene? An oral selective estrogen receptor modulator (SERM), not estrogen, FDA-approved for painful sex related to menopause.

Do vaginal lasers work for GSM? The FDA has not cleared or approved energy-based devices for this use and issued a 2018 safety communication citing insufficient safety and effectiveness evidence — a warning that remains current. This is not a first-line, established treatment.

When should vaginal dryness or painful sex be evaluated? When symptoms are persistent, not improving with basic care, or accompanied by bleeding, unusual discharge, or other concerning changes — there's no reason to wait until symptoms feel severe.

References

Current clinical guidelines

The Menopause Society (formerly NAMS) — GSM terminology and clinical guidance https://menopause.org

American College of Obstetricians and Gynecologists — Committee Opinion on Vaginal Estrogen Use in Women With a History of Breast Cancer (Obstet Gynecol. 2016;127:e93-e96)

FDA / regulatory sources

U.S. Food and Drug Administration — FDA Warns Against Use of Energy-Based Devices to Perform Vaginal "Rejuvenation" (Safety Communication, July 30, 2018) https://www.iuga.org/news/news/fda-warns-against-use-of-energy-based-devices-to-perform-vaginal-rejuvenation-or-vaginal-cosmetic-procedures-fda-safety-communication

U.S. FDA — Intrarosa (prasterone) Prescribing Information, Initial U.S. Approval 2016https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf

Systematic reviews / primary research

Faltinová M, et al. — Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: A Prospective Trial, PMC, 2024https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930867

Safety of Vaginal Estrogen in Breast Cancer Survivors: Current Evidence on Systemic Absorption and Oncologic Outcomes, ScienceDirect, 2026 https://www.sciencedirect.com/science/article/abs/pii/S0378512226000915

Efficacy and Safety of Ultra-Low-Dose 0.005% Estriol Vaginal Gel in the Prevention of Urinary Tract Infections in Postmenopausal Women with GSM, ScienceDirecthttps://www.sciencedirect.com/science/article/pii/S0378512224002238

Authoritative patient education

Harvard Health Publishing — FDA Warning on Vaginal Laser Procedures Should Emphasize Informed Choices, Not Fear https://www.health.harvard.edu/blog/fda-warning-on-vaginal-laser-procedures-should-emphasize-informed-choices-not-fear-201808022920

American Family Physician — Prasterone (Intrarosa) for Dyspareuniahttps://www.aafp.org/pubs/afp/issues/2019/0115/p117.html

Related Her Reclaim guides

• What Is Perimenopause?
• What Is Menopause?
• Surgical Menopause: What Changes Overnight
• Hormone Therapy vs. Non-Hormonal Support
• Questions to Ask Your Doctor About Perimenopause and Menopause

This is one of the most treatable parts of hormone change — and one of the least talked about. You don't need to manage it quietly, and you don't need to wait it out. Your hormones changed. You didn't.